<DOC>
	<DOC>NCT02220725</DOC>
	<brief_summary>The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Rivaroxaban.</brief_summary>
	<brief_title>A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban</brief_title>
	<detailed_description />
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Reasonably healthy men and women aged 50 to 75 History of abnormal bleeding, active bleeding or risk factors for bleeding History of thrombosis or risk factors for thrombosis History of adult asthma or use of inhaled medications</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Andexanet alpha</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Antidote</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Anti-fXa inhibitor</keyword>
	<keyword>PRT4445</keyword>
	<keyword>Xarelto</keyword>
	<keyword>Reversal agent</keyword>
</DOC>